Business Context and Reporting Period
Company: eXegenics Inc. (formerly Cytoclonal Pharmaceutics Inc.)
Filing Type: Form 10-K
Period Ended: December 31, 2004
eXegenics Inc. completed the termination of all drug discovery research and development activities during 2004. All scientific staff and administrative positions were eliminated, and all research, license, and royalty agreements were terminated. The company is currently in a wind-down phase, focused on resolving outstanding liabilities and redeploying residual assets. On September 8, 2004, the company licensed its QCT drug discovery technology to NLC Pharma, Inc. As of December 31, 2004, the company had only one employee, David E. Riggs, serving as President, CEO, and CFO.
Key Financial Metrics
| Metric | 2004 | 2003 |
|---|---|---|
| Revenue | $0 | $13,000 |
| Net Loss | $(1,926,000) | $(5,793,000) |
| Net Loss Attributable to Common Stockholders | $(2,149,000) | $(6,000,000) |
| Loss Per Share (Basic & Diluted) | $(0.13) | $(0.38) |
| Operating Expenses | $2,051,000 | $5,978,000 |
| Cash, Cash Equivalents, and Investments | $8,734,000 | $10,132,000 |
| Restricted Cash | $175,000 | $600,000 |
| Total Assets | $10,071,000 | $11,342,000 |
| Working Capital | $9,829,000 | $10,296,000 |
| Stockholders' Equity | $9,832,000 | $10,304,000 |
Note: The company reported no revenue or research and development expenses in 2004 due to the cessation of operations. Interest income was $127,000 in 2004 compared to $174,000 in 2003.
Material Changes vs. Prior Period
- Cessation of Operations: Revenue dropped 100% to $0, and R&D expenses dropped 100% to $0, as the company exited the drug discovery business.
- Expense Reduction: General and administrative expenses decreased by 30% ($887,000) to $2,051,000, driven by the termination of operations. Significant reductions included professional consulting fees ($410,000) and investor relations expenses ($517,000).
- Elimination of Merger Costs: Expenses related to merger, tender offers, and consent solicitations were $0 in 2004, compared to $2,233,000 in 2003.
- Net Loss Improvement: Net loss decreased by 67% ($3,867,000) year-over-year, primarily due to the elimination of R&D and merger-related costs.
- Delisting: The company was delisted from the Nasdaq Small Cap Market in October 2004 and is now trading on the OTC Bulletin Board.
Guidance, Outlook, and Risks
Outlook and Guidance: Management expects to use between $100,000 and $125,000 per month in 2005 to fund operations while pursuing new business opportunities. The company does not anticipate recognizing revenues from licenses in 2005. Future capital needs are uncertain, and additional financing may be required, though availability is not guaranteed.
Risks and Contingencies:
- Liquidity: While the company holds significant cash ($8.7M), future financing needs are uncertain. The company is not currently generating operating revenue.
- Legal Proceedings:
- Weiss Litigation: A class action lawsuit filed in May 2003 alleging mismanagement was dismissed with prejudice by the Delaware Court of Chancery on April 12, 2005 (subsequent to year-end).
- Labidi Proceeding: An ongoing federal lawsuit regarding employment discrimination and conversion of research materials is in the discovery phase.
- Lease Dispute: A dispute with a former landlord was settled in March 2004 with a $33,000 payment.
- Accounting Changes: The company must adopt SFAS No. 123(R) regarding share-based payments in the third quarter of 2005, which is expected to have a material impact on the statement of operations and earnings per share.
Investor Verification Checklist
- Cash Burn Rate: Verify the accuracy of the projected monthly burn rate of $100,000–$125,000 against the current cash balance of $8.7 million to determine runway.
- Legal Resolution: Confirm the final written order regarding the dismissal of the Weiss Litigation and monitor the status of the Labidi employment discrimination lawsuit.
- Strategic Pivot: Assess the progress of the "Business Opportunities Search Committee" in identifying new business ventures, as the company currently has no operating revenue.
- Accounting Impact: Review the company's selection of the adoption method for SFAS No. 123(R) to understand the potential increase in reported expenses in 2005.
- Related Party Transactions: Review the lease agreement with RFG Associates (owned by the Chairman of the Board) and the terms of the QCT technology license to NLC Pharma, Inc.